A recent pre-print review based on reviewed studies found that The use of the antiparasitic drug ivermectin could lead to a “significant reduction” in COVID-19 mortality and its use could have a “significant impact” on pandemics around the world.
For the study (pdf), published on June 17 in the American Journal of Therapeutics, a group of scientists reviewed the use of ivermectin in a clinical trial, with antiviral and anti-inflammatory trials, with 24 randomized controlled trials involving overdose. 3,400 participants. The researchers were asked to evaluate the effectiveness of ivermectin in reducing infection or mortality in people with COVID-19 or at risk of getting it.
Using multiple methods of sequential analysis, the The researchers concluded with a moderate level of confidence that the drug reduced the risk of death in COVID-19 patients by an average of 62 percent, with a 95 percent confidence level of 0.19-0.79, in a sample of 2438 patients.
Among the hospitalized COVID-19 patients, the risk of death was found 2.3 percent of those treated with the drug, compared with 7.8 percent for those who don’t, according to the review.
“Sufficient evidence shows that a significant reduction in mortality with COVID-19 is possible with ivermectin. Use of ivermectin early in the clinical course may reduce the rate of progression of severe disease., “Letter to the authors.
Since the onset of the pandemic, both observational and non-observational studies have examined ivermectin as a treatment for, and as a prevention against, COVID-19 infection. READ MORE
Listen to the insightful Thomas Paine Podcast Below –